fda depression - Search News

US FDA approves new nasal spray for depression treatment

Hosted on MSN · 51m

FDA approves Johnson & Johnson’s ketamine-derived nasal spray for depression as standalone treatment

The announcement was welcome news for those with major depressive disorder, affecting an estimated 8.3% of the adult population.

Popular Science · 10h

FDA approves first-of-its-kind nasal spray for severe depression

Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the standalone treatment of major depressive disorder (MDD), PTSD, and similar psychiatric conditions.

CNN on MSN · 1d

FDA approves standalone use of J&J’s ketamine-derived depression treatment

The U.S. Food and Drug Administration expanded approval for Johnson & Johnson’s nasal spray, Spravato, to allow it to be used as a standalone treatment for patients with severe depression, the company said on Tuesday.

J&J’s ketamine-based drug approved as standalone treatment

"Treatment-resistant depression can be very complicated, especially for patients who do not respond to oral antidepressants ...

13h

J&J’s Spravato receives FDA label expansion for depression monotherapy

Johnson & Johnson’s (J&J) nasal spray Spravato (esketamine) has received a label expansion, now approved as a monotherapy ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results